Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1392724 | 0.86 | BTK (0.48) | BTKSYKHDAC6 | |
| SCHEMBL14912294 | 0.86 | BTK (0.42) | BTKSYKHDAC6 | |
| SCHEMBL29742148 | 0.84 | BTK (0.39) | BTKSYKHDAC6 | |
| SCHEMBL14926091 | 0.83 | BTK (0.42) | BTKSYKHDAC6 | |
| SCHEMBL14929681 | 0.83 | BTK (0.40) | BTKSYKHDAC6 | |
| SCHEMBL24374744 | 0.83 | BTK (0.47) | BTKNR1H2SYKMKNK1USP30 | |
| SCHEMBL255155 | 0.81 | BTK (0.43) | BTKSYK | |
| SCHEMBL10255973 | 0.78 | NR1H2 (0.44) | BTKNR1H2IDO1TDO2MKNK1 | |
| SCHEMBL10255910 | 0.77 | MAPT (0.47) | BTKNR1H2BACE1MKNK1 | |
| SCHEMBL1392835 | 0.77 | BTK (0.44) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055019-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3521288-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| US-8921353-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2013067274-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885NR1H2 2772/4885SYK 32/4885 |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, XIAP, CBL | BTK 1/4885NR1H2 1516/4885SYK 110/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885NR1H2 2772/4885SYK 32/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | BTK 1/4885NR1H2 1686/4885SYK 10/4885 |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885NR1H2 2772/4885SYK 32/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | BTK 1/4885NR1H2 1686/4885SYK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.